Every company has a “Phase III heartbreak.” The molecule looked perfect—mechanism sound, safety profile strong—but the primary endpoint missed. Most teams bury the data. At Octavus Consulting, we treat it as a gold mine. The Opportunity in Failure Clinical failures hold information about trial design, recruitment, and patient heterogeneity that can redefine the next success. […]